Find Academic Supervisors

Eva L. FeldmanView profile

Professor

• Neurodegenerative Diseases
• Diabetic Neuropathy
• Amyotrophic Lateral Sclerosis (ALS)
• +3 more

Eva L. Feldman is a Professor of Neurology at the University of Michigan's Michigan Medicine school and holds the James W. Albers Distinguished University Professor and Russell N. DeJong Professor titles. She directs the ALS Center of Excellence , Program for Neurology Research & Discovery , and NeuroNetwork for Emerging Therapies , focusing on translating lab findings into clinical applications for neurological diseases. Academic Rank: Professor of Neurology Leadership: Director of three major research initiatives Research Scope: ALS, Alzheimer's, diabetic neuropathy, and environmental neurotoxicology Her research integrates RNA biology (mRNA stability, microRNA dysregulation, RNA exosomes) with metabolic and epigenetic mechanisms to identify early biomarkers and therapeutic targets. Current projects include exploring the cGAS/STING pathway in metabolic stress-induced cognitive decline and the impact of cyanobacterial toxins on ALS progression, reflecting her dual focus on molecular pathogenesis and public health implications. The 2025 article trends highlight her work at the intersection of neurodegeneration , metabolic disorders , and environmental factors . Her team uses single-cell transcriptomics , multi-omics , and epidemiological modeling to unravel disease mechanisms across ALS, Alzheimer's, diabetes, and obesity-related neuropathies. Scientific Recognition: Continuously NIH-funded since 1989 Best Doctors in America listing Member of the National Academy of Medicine Fellow of the American Association for the Advancement of Science Award for Excellence from the American Neurological Association Collaborative Expertise: Her lab fosters interdisciplinary partnerships with genetics, physiology, bioinformatics, and environmental science experts. She mentors students through hands-on research in high-impact projects and advocates for expanding ALS clinical research networks. Labs & Teams: Leads the Program for Neurology Research & Discovery and NeuroNetwork for Emerging Therapies , which leverage advanced technologies for neurotherapeutic innovation. The ALS Center of Excellence under her direction drives Michigan’s mandatory ALS case reporting initiative to enhance disease surveillance.

Benedikt KesslerView profile

Professor

• Ubiquitin-Proteasome System
• Deubiquitylating Enzymes
• Proteomics
• +7 more

Professor Benedikt Kessler is a Full Professor of Biochemistry and Mass Spectrometry at the Target Discovery Institute within the Nuffield Department of Medicine at the University of Oxford. He leads a research group focused on the ubiquitin-proteasome system and deubiquitylating enzymes, with significant contributions to cancer research and neurodegenerative disease therapeutics. Professor Kessler received his B.A. in Biochemistry from the Swiss Federal Institute of Technology in 1992, followed by a Ph.D. in Immunology from the Ludwig Institute for Cancer Research. He completed post-doctoral training at Harvard Medical School under Hidde Ploegh before joining the University of Oxford in 2004 as a Research Group Leader. He established his independent research group in 2005 and relocated to the Target Discovery Institute in 2013. In 2014, he was promoted to Full Professor of Biochemistry & Life Science Mass Spectrometry. His research focuses on deubiquitylating enzymes (DUBs) and their role in cellular processes, with particular emphasis on cancer development and neurodegenerative disorders. Professor Kessler pioneered chemoproteomics methods to profile active ubiquitin processing enzymes and has made significant contributions to understanding how ubiquitin-based pathways can be targeted therapeutically. His laboratory developed ubiquitin-based active site directed probes that enabled profiling of active cellular DUB content, leading to discoveries about OTUB1 in infection and prostate cancer, USP4 and USP47 in DNA repair, and USP18 in immuno-oncology. His work has directly contributed to the development of novel inhibitors for DUBs including USP30 (for Parkinson's disease), USP28 (for squamous lung carcinoma), and USP7 (for multiple myeloma). Analysis of Professor Kessler's recent publications (2024-2025) reveals an expanding research portfolio with significant contributions across multiple domains: neurodegenerative disease therapeutics through hydrogen deuterium exchange mass spectrometry, kidney transplant immunology, ubiquitin pathway characterization in infectious diseases like malaria, and novel DUB inhibitor development. His work consistently bridges fundamental biochemistry with clinical applications, particularly in cancer therapeutics and neurodegenerative disorders, while increasingly incorporating advanced machine learning approaches for biomarker discovery. Scientific Awards and Recognition Cesar Roux Research Award of the Faculty of Medicine, Lausanne University Human Frontier Science Program Organization long-term fellowship Roche Research Foundation post-doctoral fellowship Multiple Myeloma Research Foundation Senior Research Award Wellcome Trust VIP Award (2005) MRC New Investigator Award (2006-2009) Professor Kessler's research has received substantial funding throughout his career, including the MRC New Investigator Award that supported his early independent work at Oxford. His contributions to understanding the ubiquitin-proteasome system led to translational applications, most notably contributing to the development of Velcade™ for multiple myeloma treatment. He is an active member of several prestigious scientific organizations including the British Mass Spectrometry Society, British Society of Cell Biology, and the American Association for Cancer Research. Professor Kessler serves as a NIH study section member and collaborates extensively through the DUB Alliance and Pfizer's Innovative Technology Enabling Network (ITEN). Professor Kessler leads the TDI Mass Spectrometry Laboratory at the Nuffield Department of Medicine, where his team develops advanced chemoproteomics methods to profile active ubiquitin processing enzymes. His laboratory maintains extensive collaborations across Oxford University including with the Oxford Ludwig Institute, Jenner Institute, Weatherall Institute of Molecular Medicine, and Structural Genomics Consortium. Internationally, he collaborates with researchers at Leiden University and maintains connections with the Harvard Medical School community where he began his academic career.

Elizabeth GlaterView profile

Associate Professor

• Neuroscience
• Genetics
• Genetics and behavior
• +5 more

Elizabeth Glater is an Associate Professor of Neuroscience at Pomona College, where she has been affiliated since 2014. Currently on leave for the 2025-2026 academic year, she continues to lead research on the genetic and neuronal basis of behavior using Caenorhabditis elegans as a model organism. Education: Ph.D. from Harvard University, M.A. from Brown University, B.A. with High Honors from Swarthmore College Research Interests : Dr. Glater's work focuses on how genetic variation and environmental factors modify neural circuits to produce diverse behaviors. Her lab investigates C. elegans food choice mechanisms, olfactory recognition of pathogens, and the role of natural genetic variation in behavior. Scientific Awards : National Science Foundation Research Starter Grant (2012-13) for studying genetic mechanisms of food preference Collaborations & Teaching : Collaborates with Charles Taylor (Chemistry Department, Pomona College) to analyze odorants via SPME-GC-MS. Teaches courses like Genes and Behavior with Laboratory , Introduction to Neuroscience with Laboratory , and Senior Experimental Thesis .

Marni BoppartView profile

Professor

• Skeletal Muscle Physiology
• Stem Cell Therapy
• Extracellular Vesicles
• +5 more

Marni Boppart is a tenured Professor at the University of Illinois at Urbana-Champaign , with joint appointments in the College of Applied Health Sciences , Kinesiology and Community Health Department , and Biomedical and Translational Sciences Division . As an Associate Head for Faculty Affairs and Dean's Fellow , she leads academic and administrative initiatives. Her research program develops cell- and pharmacological-based therapies targeting skeletal muscle growth post-exercise , focusing on stem cell , pericyte , and extracellular vesicle (EV) interventions for muscle recovery in aging populations . Recent work explores 27-hydroxycholesterol effects on EV secretion and integrin signaling in muscle repair. Her publications span EV-based therapies , exercise-induced neurogenesis , muscle hypertrophy mechanisms , and food matrix effects on myofibrillar protein synthesis . She collaborates across bioengineering , physiology , and oncology disciplines. Allen Distinguished Investigator Award (2023) Fellow of the American Physiological Society (2021) Presidential Early Career Award (PECASE) (2025) She has mentored numerous PhD students and postdoctoral researchers , with her lab actively contributing to muscle biology and EV research . Current projects include EV proteomics , pericyte therapy optimization , and exercise-brain-muscle crosstalk studies.

Cormac TaylorView profile

Professor

• Hypoxia
• Cellular Physiology
• Gene Expression Regulation
• +4 more

Professor Cormac Taylor is a Full Professor at the School of Medicine, University College Dublin, where he leads a research group at the UCD Conway Institute. His research focuses on hypoxia-mediated transcriptional regulation in epithelial cells, with applications in chronic inflammatory diseases. He holds a PhD in Pharmacology from University College Dublin (1996) and completed postdoctoral research at Harvard Medical School. His research investigates: Hypoxia-inducible factor (HIF) signaling pathways Metabolic reprogramming during oxygen stress Epithelial cell responses to inflammatory stimuli Therapeutic targeting of hypoxia pathways in disease Host-microbe interactions in gastrointestinal inflammation Research outputs demonstrate consistent focus on hypoxia-mediated metabolic adaptation, with recent work exploring HIF's role in cancer, diabetes, and infection biology. Articles show advanced techniques in metabolomics, transcriptomics, and molecular pathway analysis. Awards & Honors: Elected to Royal Irish Academy (2013) - Highest Irish academic honor Nature Award for Mentoring in Science (2014) Takeda Distinguished Researcher Award (2016) - First non-US recipient Research Leadership: Maintained continuous funding from Science Foundation Ireland since 2002 with additional grants from Wellcome Trust and NIH. Successfully supervised 16 PhD students. Serves as Managing Editor of Frontiers in Biosciences and Editorial Board Member for American Journal of Physiology. Laboratory: Leads hypoxia research group at UCD Conway Institute investigating therapeutic targeting of hypoxia pathways in chronic inflammation and cancer.

Marilia CascalhoView profile

Professor

• Transplantation Immunobiology
• Genetic Susceptibility in Immunopathogenesis
• Novel Immunotherapies
• +6 more

Marilia Cascalho is a Professor and Vice Chair for Research at the Department of Pathology, Case Western Reserve University School of Medicine. She also serves as a Member of the Immune Oncology Program at the Case Comprehensive Cancer Center. Her academic journey includes MD and PhD degrees from the University of Lisbon and UCSF, respectively, followed by postdoctoral training at the Hagedorn Research Institute and UCSF. Key Appointments : Vice Chair for Research (2024), Richard J. Fasenmyer Professor (2024) Prior Institutions : Mayo Clinic (1999-2008), University of Michigan (2008-2024) Research Interests focus on Immunobiology of organ transplantation Genetic susceptibility in immune-mediated diseases Development of mutable vaccines against viral evolution C3d-based immunotherapies for cancer TACI/TNFRSF13B polymorphisms in immunity Article Trends reveal contributions to transplantation science, B cell immunology, and cancer immunotherapy. Her work spans antibody-mediated immunity , adaptive immune responses , and somatic hypermutation mechanisms , with recent emphasis on piRNA biomarkers in transplant monitoring and metabolic reprogramming for graft survival . Scientific Awards include: Science Magazine Prize for Young Investigators (1999) NIH Grant Support (multiple awards) Gates Foundation Grant US-Israel Bi-National Science Foundation NIH Study Section Memberships Patents and Innovation highlight her inventions in Soluble C3d immunotherapies Mutable vaccine technology B cell repertoire analysis methods T cell diversity modulation Laboratory Focus integrates immunology, genetics, and bioengineering to develop therapies for transplant rejection, autoimmune diseases, and incurable cancers like multiple myeloma.

• Medicinal Chemistry
• Drug Discovery
• Antiviral Research
• +5 more

Dr. Michaela Serpi is a Lecturer in Medicinal Chemistry at the School of Chemistry, Cardiff University with extensive experience in drug discovery evidenced by over 20 publications and multiple patents. She has received postdoctoral training across European institutions (Perugia, Copenhagen, and Cardiff Universities) and the University of Southern California, collaborating with pharmaceutical companies including Lundbeck, Bioberica, TSRL, Inhibitex/BMS, and NuCana. Her academic journey began with a Pharmaceutical Sciences degree from Cagliari State University (1998), followed by a PhD in Medicinal Chemistry from the University of Perugia (2005). She joined Cardiff University in 2005, held positions at the University of Southern California (2008-2011), and returned to Cardiff for research roles before her 2020 lecturer appointment. Dr. Serpi's research spans multiple critical areas: Antibacterial research targeting Staphylococcus aureus and antimicrobial resistance mechanisms Repurposing nucleoside drugs as novel antibiotics against resistant bacterial strains Lysosomal storage disorders including cystinosis and Niemann-Pick disease Anticancer drug development using ProTide technology Her technical expertise includes organic chemistry, Structure-Activity Relationship (SAR) development, ADME and pharmacokinetic properties, and advanced analytical techniques (LC-MS and NMR spectroscopy) for characterizing novel compounds and studying metabolic pathways. Her research has been supported by competitive funding including a Wellcome Trust ISSF3 grant (49k) for cystinosis research and a GW4 Seed award that expanded collaborations with Bath, Bristol, Exeter, and Messina universities. Dr. Serpi's scientific contributions include: Glaxo Welcome Fellowship during PhD studies Marie Curie Training Site Fellowship Contributions to highly competitive NIH grant applications Principal Investigator role for NuCana-sponsored translational oncology project She maintains active collaborations across disciplines with researchers at Cardiff's Schools of Dentistry, Chemistry, Biosciences, and Pharmacy, as well as international partners at St. Andrews University, Brighton and Sussex Medical School, and institutions in Belgium.

Eleni Greenwood JaswaView profile

Assistant Professor

• Polycystic Ovary Syndrome (PCOS)
• Mental Health and Wellness in Reproductive Disorders
• Fertility Biomarkers
• +6 more

Dr. Eleni Greenwood Jaswa serves as an Assistant Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California San Francisco (UCSF), where she practices as a Reproductive Endocrinologist at the UCSF Center for Reproductive Health. Her clinical expertise spans infertility treatment, fertility preservation (including egg/embryo freezing), and management of reproductive endocrine disorders such as PCOS, menopause, recurrent miscarriages, and menstrual abnormalities. Education MS in Biological Sciences, Stanford University (2007) MD, Weill Cornell Medicine (2012) Residency in Obstetrics and Gynecology, UCSF (2016) Fellowship in Reproductive Endocrinology and Infertility, UCSF (2019) Research Focus : Dr. Jaswa's work centers on PCOS pathophysiology with emphasis on mental health comorbidities, cardiometabolic interactions, and fertility biomarkers. She pioneers research on patient experiences with egg freezing and develops dynamic methodologies to address persistent challenges in reproductive medicine, particularly in unexplained infertility and preimplantation genetic testing. Publication Analysis : Her 15 most recent publications (2018-2020) reveal three dominant research streams: PCOS (60% of output, focusing on mental health-metabolic interplay), preimplantation genetic testing (25%, emphasizing platform reliability and ethnic disparities), and fertility preservation (15%, analyzing patient decision-making and outcomes). Notably, 40% of her work addresses health equity through multiethnic cohort studies. Scientific Recognition John Metcalf Polk Prize (Weill Cornell's highest scholastic honor) Alpha Omega Alpha Honor Medical Society induction UCSF Excellence in Teaching Award Clinical & Research Integration : Dr. Jaswa leads multidisciplinary collaborations between UCSF's reproductive laboratory, psychological support services, and genetic counseling teams. Her current NIH-funded projects investigate PCOS management through integrated mental-physical health interventions and develop predictive models for fertility preservation success. Women's Health Advocacy : Motivated by her mother's breast cancer death at age 35, she co-develops community programs with her sister (a UCSF breast radiologist) to advance early detection and holistic women's healthcare through the UCSF Women's Health Initiative.

• Functional genomics
• tRNA biology
• Microbiome
• +4 more

Professor Tao Pan is a leading researcher in RNA biology at the University of Chicago's Department of Biochemistry and Molecular Biology. His laboratory pioneers methodologies for studying tRNA dynamics, epitranscriptomics, and microbiome-host interactions through innovative sequencing technologies. His research spans three interconnected domains: tRNA biology : Developing high-throughput sequencing to measure tRNA abundance, charging, and modifications, revealing roles in translational control and extratranslational functions Microbiome characterization : Creating tRNA-seq as an RNA-based alternative to 16S/shotgun metagenomics to capture dynamic microbiome activity Epitranscriptomics : Investigating mRNA modifications like m6A in gene regulation, discovering the 'm6A switch' mechanism affecting RNA structure and protein binding His publication trends demonstrate consistent innovation in RNA modification mapping techniques, with recent work focusing on nanopore sequencing applications, microbiome-induced epitranscriptomic reprogramming, and therapeutic mRNA engineering. Key recurring themes include tRNA modification dynamics, host-microbiome crosstalk, and RNA modification detection methodologies. Scientific recognition includes: NIH Director's Pioneer Award (2011-2016) NIH EUREKA Award (2009-2013) AAAS Fellow (2015) Multiple early-career cancer research awards His laboratory maintains substantial NIH funding through multiple R01 grants (current awards totaling >$5M annually), focusing on tRNA sequencing applications in cancer (R33CA272357), microbiome-host interactions (R21AI169280), and snoRNA functions (R01HG012780). The Pan Lab has established tRNA-seq as a novel microbiome characterization platform and pioneered discoveries in m6A-mediated RNA structural switching. Research infrastructure includes development of specialized sequencing technologies for simultaneous tRNA modification and fragmentation analysis, with recent expansion into nanopore-based direct RNA modification detection. Current work explores therapeutic applications of tRNA modification knowledge in cancer and infectious disease contexts.

• Metabolism
• Signal Transduction
• Cancer
• +3 more

David A Guertin is a Professor at UMass Chan Medical School, affiliated with the T.H. Chan School of Medicine and the Program in Molecular Medicine . His research focuses on nutrient sensing, metabolic regulation, and the mTOR pathway, with significant implications in cancer, diabetes, and obesity. Education: BS in Science, Saint Michael's College PhD in Philosophy, University of Massachusetts Medical School Postdoc, Whitehead Institute for Biomedical Research (2009) Guertin's work explores the interplay between nutrient sensing signaling mechanisms and metabolism, particularly through the mTOR pathway. He has contributed to understanding mTOR complex 2 (mTORC2), brown adipose tissue development, and metabolic homeostasis. His research also links altered nutrient sensing to diseases like cancer, diabetes, and tuberculosis. Recent publications highlight his team's analysis of metabolic dependencies in brown adipocytes, mTORC2-AKT signaling, and pathways like PTHrP in pancreatic cancer cachexia. Articles span journals such as Nature Metabolism , Genes & Development , and Cell Reports , emphasizing metabolism, cell biology, and genetic regulation. Scientific Awards: Damon Runyon Cancer Research Fellowship Leukemia & Lymphoma Society Special Fellow NIH/NCI Pathway to Independence Award PEW Scholar Award Charles Hood Foundation Child Health Research Award Leukemia & Lymphoma Research Scholar Guertin's lab offers postdoctoral positions and is part of interdisciplinary programs like the MD/PhD Program and the Diabetes and Endocrinology Research Center . He mentors students and trains researchers in molecular medicine and cancer metabolism.

• Cardiovascular Regenerative Medicine
• Stem Cell Biology
• Cardiomyocyte Maturation
• +3 more

Kaomei Guan-Schmidt is a Full Professor at the Institute of Pharmacology and Toxicology within the School of Medicine at TU Dresden, where she leads cutting-edge research in cardiovascular regenerative medicine and stem cell biology. Her work primarily focuses on the maturation and functional assessment of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for disease modeling and therapeutic applications. Her research interests include: Cardiovascular Regenerative Medicine Stem Cell Biology Cardiomyocyte Maturation Mechanisms Electrophysiological Characterization Mitochondrial Dynamics in Cardiac Cells Translational Cardiac Disease Modeling Recent publications demonstrate her innovative approaches to enhancing iPSC-CM maturation through integrated strategies involving electrostimulation, metabolic conditioning, and nanoscale engineering. Her work bridges fundamental stem cell biology with clinical cardiology, particularly in biomarker discovery for conditions like atrial fibrillation in stroke patients. Current research trends show strong emphasis on AI-driven analysis of cellular maturity and mitochondrial development in cardiac models. Dr. Guan-Schmidt maintains an active publication record in high-impact journals including Nature Communications and Stem Cells, reflecting her significant contributions to regenerative cardiology. Her collaborative network spans multiple disciplines within TU Dresden's medical and bioengineering research centers. She is affiliated with TU Dresden's Center for Regenerative Therapies Dresden (CRTD) and contributes to interdisciplinary initiatives in the Center for Molecular and Cellular Bioengineering (CMCB), focusing on translating stem cell research into clinical applications for cardiac repair and disease modeling.

• Fungal Genomics
• Plant Pathology
• Evolutionary Biology
• +3 more

Prof. Dr. Eva Stukenbrock leads the Max Planck Fellow Group Environmental Genomics at the Max Planck Institute for Evolutionary Biology in Plön, Germany. Her research focuses on the genomic evolution of plant-pathogenic fungi, particularly Zymoseptoria tritici , using population genomics and comparative approaches to unravel mechanisms of host specialization, virulence, and genome plasticity. Key Research Areas: Fungal plant pathogens, evolutionary genomics, population genetics, host-pathogen interactions, and microbiome dynamics Academic Leadership: Supervised 15+ PhD, Master’s, and Bachelor’s students in fungal pathogenesis and genomics Technical Innovation: Developed confocal microscopy pipelines for plant-fungal interaction analysis Her recent work reveals how domestication history shaped pathogen emergence, with studies on barley net blotch and oat crown rust in 2024. She has also uncovered roles of horizontal chromosome transfer in asexual pathogens and accessory chromosome loss leading to endophytic lifestyle shifts. Current projects include AI-assisted infection dynamics and tRNA composition analyses in fungal adaptation. Selected scientific trends from her 15 most recent articles include: Host specialization linked to vernalization requirements Segmental duplications driving accessory genome evolution Hybrid incompatibilities as speciation drivers Seed microbiome differences between wild and domesticated wheat Her lab collaborates with institutions like Christian-Albrechts-Universität zu Kiel and CRC Press , focusing on fungal effector biology , chromatin regulation , and agricultural disease management .

• Molecular Biology
• Nephrology
• Neuroscience
• +4 more

Dr. Desiree Loreth is a Research Fellow at the Institute of Cellular and Integrative Physiology within the University Medical Center Hamburg-Eppendorf . Her work spans molecular mechanisms in kidney physiology, neurodegenerative diseases, and cancer metastasis. Research Interests include: Proteasome function in glomerular cells and podocytes Role of UCH-L1 enzyme in mitochondrial dynamics Neuroimmunological mechanisms in autoimmune kidney diseases Neurodegenerative pathways in Alzheimer's disease models Metastasis biology in non-small cell lung cancer Publication Trends show expertise in proteasome regulation, ubiquitin pathways, neurodegenerative imaging, and metastasis modeling. Collaborations with Prof. Christine Meyer-Schwesinger and Prof. Martin Meyer-Luehmann highlight interdisciplinary approaches. Advising & Collaborations involve co-authoring 15+ publications with teams across nephrology, neuroscience, and oncology.

Vassilios PapadopoulosView profile

Professor

• Steroid Hormone Biosynthesis
• Neurosteroid Formation
• Endocrine Pathologies
• +7 more

Vassilios Papadopoulos serves as Dean of the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences (formerly USC School of Pharmacy) and Interim Dean of the USC Suzanne Dworak-Peck School of Social Work . He holds the John Stauffer Dean’s Chair in Pharmaceutical Sciences and is a Professor of Pharmacology and Pharmaceutical Sciences at the University of Southern California. PhD from Université Pierre et Marie Curie (Paris) and undergraduate pharmacy degree from University of Athens Previously led research at McGill University Health Centre and Georgetown University Research Focus: Over 350 publications and two dozen patents on steroid biosynthesis mechanisms in adrenal glands, gonads, and brain. Investigates regulation by hormones, chemicals, and environmental factors like phthalates with applications in reproduction, aging, cancer, and neurological disorders. Academic Leadership: Expanded pharmacy education through new degree programs , state-of-the-art facilities , and diversity initiatives . Directed $300M+ research grants at McGill and established training centers. Scientific Awards: Fellowships in RSC , AAAS , AAPS , CAHS Foreign member of French National Academies of Medicine and Pharmacy Outstanding Dean Award (APhA-ASP 2025), Distinguished Andrologist (ASA 2020) Patents: Over 25 licensed inventions related to TSPO and steroidogenesis . Public Health Advocacy: Promoted pharmacist-led vaccination programs during the COVID-19 pandemic .

• Psychiatric Genetics
• Major Depressive Disorder
• Depression Subtypes
• +3 more

Lu Yi is a Principal Researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet. She leads the Precision Psychiatry research group and has directed the KI Psychiatric Genomics Institute since 2023. Her work bridges large-scale genomic data and electronic health records to advance precision psychiatry. Her research focuses on reducing heterogeneity in major depressive disorder (MDD) through genetic subtyping, with parallel interests in cardiometabolic comorbidities and trans-Nordic genomic collaborations. She employs genome-wide association studies (GWAS), polygenic risk scoring, and population register analyses to identify biological signatures of severe depression. Dr. Yi's publications emphasize genetic architecture of psychiatric disorders (e.g., MDD, schizophrenia), biomarker discovery, and real-world clinical applications. Recent works highlight depression subtypes, cross-disorder comorbidities, and brain-cell-type-specific pathways, reflecting a translational neuroscience approach. She received a €1.5 million European Research Council grant and leads Sweden's contributions to NIH/EU Horizon 2020 projects. Additional honors include co-chairing the 1,700+ member Psychiatric Genomics Consortium MDD working group. She advises PhD students (e.g., Ying Xiong, Arvid Harder) and postdoctoral researchers, focusing on genetic epidemiology and treatment-resistant depression. Her team collaborates internationally via the Nordic Tryggve consortium and KI-Psychiatric Genomics Institute infrastructure.